ADMA has received FDA approval for their production yield. This will have them have a 20% increase in both ASCENIV and BIVIGAM. This yield increase will help them in their total revenue and in their gross margin. This has led to a 12% jump in the price today.
Forward looking pipeline has SG-001 a hyperimmune globulin targeting S. pnemonia. Which is pre-clinical but promising new way to treat infectious diseases.
Drew,
Long ADMA